Jones Financial Companies
MYGN icon

Jones Financial Companies’s Myriad Genetics MYGN Stock Holding History

Jones Financial Companies’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7K Buy
3,018
+253
+9% +$1.15K ﹤0.01% 3560
2026
Q1 		$11.8K Buy
2,765
+14
+0.5% +$73 ﹤0.01% 3520
2025
Q4 		$16.9K Buy
2,751
+145
+6% +$1.05K ﹤0.01% 3007
2025
Q3 		$20.1K Buy
2,606
+1,882
+260% +$11.2K ﹤0.01% 2798
2025
Q2 		$3.8K Buy
724
+88
+14% +$520 ﹤0.01% 3234
2025
Q1 		$5.65K Sell
636
-954
-60% -$11.5K ﹤0.01% 2918
2024
Q4 		$21.8K Buy
1,590
+36
+2% +$664 ﹤0.01% 2221
2024
Q3 		$41.1K Buy
1,554
+394
+34% +$10.7K ﹤0.01% 1712
2024
Q2 		$28.4K Buy
+1,160
New +$25.5K ﹤0.01% 1434
2024
Q1 		– Sell
-106
Closed -$2.03K – 1418
2023
Q4 		$2.03K Buy
106
+65
+159% +$1.12K ﹤0.01% 906
2023
Q3 		$658 Buy
+41
New +$780 ﹤0.01% 658
2021
Q4 		– Sell
-60
Closed -$2K – 767
2021
Q3 		$2K Buy
+60
New +$1.99K ﹤0.01% 622

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jones Financial Companies's MYGN Position: Q2 2026 in Review

Jones Financial Companies increased its Myriad Genetics (MYGN) stake by 9.2% in Q2 2026, buying an estimated $1.15K and bringing the position to 3,018 shares worth $17.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3560.

Jones Financial Companies first reported a position in MYGN in Q3 2021 and has held it in 12 quarters since. The position peaked at $41.1K in Q3 2024. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Jones Financial Companies held 3,018 shares of Myriad Genetics worth $17.7K as of Q2 2026.
  • Jones Financial Companies bought 253 Myriad Genetics shares in Q2 2026, an estimated $1.15K.
  • Myriad Genetics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3560 holding.
  • Jones Financial Companies first reported a position in Myriad Genetics in Q3 2021 and has held it in 12 quarters since.
  • Jones Financial Companies's Myriad Genetics position peaked at $41.1K in Q3 2024.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.